Stock DNA
Pharmaceuticals & Biotechnology
RON 5,097 Million ()
NA (Loss Making)
NA
0.00%
-999,999.00
-1.06%
11.79
Revenue and Profits:
Net Sales:
778 Million
(Quarterly Results - Mar 2025)
Net Profit:
11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-79.37%
0%
-79.37%
6 Months
-79.37%
0%
-79.37%
1 Year
-79.37%
0%
-79.37%
2 Years
-79.37%
0%
-79.37%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Med Life SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
24.71%
EBIT Growth (5y)
11.56%
EBIT to Interest (avg)
3.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.97
Sales to Capital Employed (avg)
0
Tax Ratio
62.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.54%
ROE (avg)
15.58%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.99
EV to EBIT
40.07
EV to EBITDA
13.35
EV to Capital Employed
3.10
EV to Sales
1.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.73%
ROE (Latest)
-1.43%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
777.60
736.90
5.52%
Operating Profit (PBDIT) excl Other Income
113.00
102.80
9.92%
Interest
24.00
24.00
Exceptional Items
-1.50
-0.80
-87.50%
Consolidate Net Profit
10.60
-4.10
358.54%
Operating Profit Margin (Excl OI)
56.40%
34.30%
2.21%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is 5.52% vs 10.26% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 358.54% vs -220.59% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,715.60
2,210.40
22.86%
Operating Profit (PBDIT) excl Other Income
387.90
279.60
38.73%
Interest
102.60
82.20
24.82%
Exceptional Items
-2.40
-4.70
48.94%
Consolidate Net Profit
16.80
-4.20
500.00%
Operating Profit Margin (Excl OI)
49.30%
38.40%
1.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 22.86% vs 23.11% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 500.00% vs -111.23% in Dec 2023






